Quantum Genomics Société Anonyme (QNNTF)
USD 0.1
(0.0%)
USD 0.1
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.13 Million USD | -82.52% |
| 2022 | 23.65 Million EUR | -2.01% |
| 2021 | 24.14 Million USD | -39.84% |
| 2020 | 40.13 Million USD | 165.68% |
| 2019 | 15.1 Million EUR | -28.49% |
| 2018 | 21.12 Million USD | 26.44% |
| 2017 | 16.7 Million USD | 9.18% |
| 2016 | 15.3 Million USD | 33.66% |
| 2015 | 11.44 Million USD | 99.1% |
| 2014 | 5.75 Million USD | 146.55% |
| 2013 | 2.33 Million USD | 67.45% |
| 2012 | 1.39 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q3 | 3.74 Million EUR | -34.9% |
| 2023 Q4 | 3.74 Million EUR | 0.0% |
| 2023 FY | 4.13 Million USD | -82.52% |
| 2023 Q2 | 5.75 Million EUR | 0.0% |
| 2023 Q1 | 5.75 Million EUR | -75.67% |
| 2022 Q1 | 27.05 Million EUR | 27.38% |
| 2022 Q4 | 23.65 Million EUR | -0.0% |
| 2022 FY | 23.65 Million EUR | -2.01% |
| 2022 Q3 | 23.65 Million EUR | -12.57% |
| 2022 Q2 | 27.05 Million EUR | 0.0% |
| 2021 Q1 | 32.41 Million EUR | -1.17% |
| 2021 FY | 24.14 Million USD | -39.84% |
| 2021 Q4 | 21.24 Million EUR | 0.0% |
| 2021 Q3 | 21.24 Million EUR | -34.48% |
| 2021 Q2 | 32.41 Million EUR | 0.0% |
| 2020 Q1 | 18.54 Million EUR | 22.77% |
| 2020 Q2 | 18.54 Million EUR | 0.0% |
| 2020 Q4 | 32.8 Million EUR | 0.0% |
| 2020 FY | 40.13 Million USD | 165.68% |
| 2020 Q3 | 32.8 Million EUR | 76.86% |
| 2019 Q1 | 16.58 Million EUR | -10.28% |
| 2019 FY | 15.1 Million EUR | -28.49% |
| 2019 Q3 | 15.1 Million EUR | -8.89% |
| 2019 Q2 | 16.58 Million EUR | 0.0% |
| 2019 Q4 | 15.1 Million EUR | 0.0% |
| 2018 Q3 | 18.48 Million EUR | 91.02% |
| 2018 Q1 | 9.67 Million EUR | -30.49% |
| 2018 Q2 | 9.67 Million EUR | 0.0% |
| 2018 Q4 | 18.48 Million EUR | 0.0% |
| 2018 FY | 21.12 Million USD | 26.44% |
| 2017 Q2 | 10.69 Million EUR | 0.0% |
| 2017 FY | 16.7 Million USD | 9.18% |
| 2017 Q4 | 13.91 Million EUR | 0.0% |
| 2017 Q1 | 10.69 Million EUR | -26.28% |
| 2017 Q3 | 13.91 Million EUR | 30.1% |
| 2016 Q3 | 14.51 Million EUR | -8.42% |
| 2016 Q4 | 14.51 Million EUR | 0.0% |
| 2016 FY | 15.3 Million USD | 33.66% |
| 2016 Q2 | 15.84 Million EUR | 0.0% |
| 2016 Q1 | 15.84 Million EUR | 50.33% |
| 2015 Q3 | 10.54 Million EUR | -18.25% |
| 2015 FY | 11.44 Million USD | 99.1% |
| 2015 Q1 | 12.89 Million EUR | 171.3% |
| 2015 Q4 | 10.54 Million EUR | 0.0% |
| 2015 Q2 | 12.89 Million EUR | 0.0% |
| 2014 Q1 | 2.74 Million EUR | 62.06% |
| 2014 Q4 | 4.75 Million EUR | 0.0% |
| 2014 Q2 | 2.74 Million EUR | 0.0% |
| 2014 Q3 | 4.75 Million EUR | 73.25% |
| 2014 FY | 5.75 Million USD | 146.55% |
| 2013 Q3 | 1.69 Million EUR | 0.0% |
| 2013 FY | 2.33 Million USD | 67.45% |
| 2013 Q4 | 1.69 Million EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2012 FY | 1.39 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 89.354% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 42.72% |
| SQZ Biotechnologies Company | 107.18 Million USD | 96.142% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 60.816% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 96.824% |
| Mesoblast Limited | 667.9 Million USD | 99.381% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -5614.725% |
| Genus plc | 1.02 Billion USD | 99.598% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -204.447% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -728.685% |
| Marizyme, Inc. | 22.01 Million USD | 81.215% |
| ContraFect Corporation | 20.67 Million USD | 80.002% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -559.563% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -959.38% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -982.08% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -188.783% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 0.255% |
| MultiCell Technologies, Inc. | 126.22 USD | -3276291.222% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -340.088% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 96.782% |
| EV Biologics, Inc. | 431.71 Thousand USD | -857.917% |
| Q BioMed Inc. | 3.51 Million USD | -17.635% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 88.245% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -436.624% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -1482.788% |
| Biomind Labs Inc. | 73.81 Thousand USD | -5502.163% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 99.107% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 86.222% |
| Skye Bioscience, Inc. | 11.94 Million USD | 65.366% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -24.825% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -50.581% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -111.188% |
| IMV Inc. | 31.33 Million USD | 86.802% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -501.534% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -58.861% |
| GB Sciences, Inc. | 103.44 Thousand USD | -3897.855% |
| Alpha Cognition Inc. | 2.45 Million USD | -68.645% |
| HST Global, Inc. | 1526.00 USD | -270900.066% |
| CSL Limited | 38.02 Billion USD | 99.989% |
| Halberd Corporation | 10.13 Thousand USD | -40719.87% |
| Enzolytics Inc. | 361.7 Million USD | 98.857% |
| Resverlogix Corp. | 8.11 Million USD | 49.039% |
| Affymax, Inc. | 7.44 Million USD | 44.438% |
| SYBLEU INC | 330.46 Thousand USD | -1151.395% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -120.22% |
| argenx SE | 4.54 Billion USD | 99.909% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 85.201% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 91.331% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -18053.114% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 53.789% |
| AVAX Technologies, Inc. | 7.37 Million USD | 43.942% |
| Zenith Capital Corp. | 7410.00 USD | -55709.19% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.878% |
| Ember Therapeutics, Inc. | 184.00 USD | -2247433.152% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -1185.079% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -1482.261% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.073% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -185.432% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -36.706% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 92.153% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -345.65% |
| BioStem Technologies, Inc. | 14.56 Million USD | 71.598% |
| ONE Bio Corp. | 70.08 Million USD | 94.099% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -7143.25% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -178924.286% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -318.583% |
| Agentix Corp. | 261.39 Thousand USD | -1482.092% |
| LadRx Corporation | 2.3 Million USD | -79.189% |
| Cell Source, Inc. | 195.17 Thousand USD | -2018.891% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -760.556% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1069.475% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1069.475% |
| NovAccess Global Inc. | 62.24 Thousand USD | -6543.524% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -546.513% |
| Itoco Inc. | 1.4 Million USD | -195.375% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -4223.218% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -3801.378% |
| Kadimastem Ltd | 2.3 Million USD | -79.484% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -5316.168% |
| CytoDyn Inc. | 11.13 Million USD | 62.864% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -2792.497% |
| Mobile Lads Corp. | 52.00 USD | -7952709.615% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -23028.977% |
| Qrons Inc. | 420.00 USD | -984533.571% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -972.833% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -649.015% |
| Rebus Holdings, Inc. | 5000.00 USD | -82609.22% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -910.073% |
| International Stem Cell Corporation | 5.39 Million USD | 23.275% |
| Bioxytran, Inc. | 137.63 Thousand USD | -2904.592% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 72.434% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 75.056% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -5134.761% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -378.267% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 44.985% |
| Neutra Corp. | 2851.00 USD | -144952.999% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 87.239% |
| PureTech Health plc | 693.97 Million USD | 99.404% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 48.762% |
| IXICO plc | 15.84 Million USD | 73.899% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 50.067% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 95.998% |
| CSL Limited | 38.02 Billion USD | 99.989% |
| Cellectis S.A. | 333.99 Million USD | 98.762% |